Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids.
OBJECTIVE
To determine the in vitro kinetics of morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) formation and the inhibition potential by methadone enantiomers and structurally related opioids.


METHODS
M3G and M6G formation kinetics from morphine were determined using microsomes from five human livers. Inhibition of glucuronide formation was investigated with eight inhibitors (100 microm) and the mechanism of inhibition determined for (R)- and (S)-methadone (70-500 microm) using three microsomal samples.


RESULTS
Glucuronide formation displayed single enzyme kinetics. The M3G Vmax (mean+/-SD) was 4.8-fold greater than M6G Vmax (555+/-110 vs. 115+/-19 nmol mg-1 protein h-1; P=0.006, mean of difference 439; 95% confidence interval 313, 565 nmol mg-1 protein h-1). Km values for M3G and M6G formation were not significantly different (1.12+/-0.37 vs. 1.11+/-0.31 mm; P=0.89, 0.02; -0.29, 0.32 mm). M3G and M6G formation was inhibited (P<0.01) with a significant increase in the M3G/M6G ratio (P<0.01) for all compounds tested. Detailed analysis with (R)- and (S)-methadone revealed noncompetitive inhibition with (R)-methadone Ki of 320+/-42 microm and 192+/-12 microm for M3G and M6G, respectively, and (S)-methadone Ki of 226+/-30 microm and 152+/-20 microm for M3G and M6G, respectively. Ki values for M3G inhibition were significantly greater than for M6G for (R)-methadone (P=0.017, 128; 55, 202 microm) and (S)-methadone (P=0.026, 75; 22, 128 microm).


CONCLUSIONS
Both methadone enantiomers noncompetitively inhibited the formation of morphine's primary metabolites, with greater inhibition of M6G formation compared with M3G. These findings indicate a mechanism for reduced morphine clearance in methadone-maintained patients and reduced relative formation of the opioid active M6G compared with M3G.
Morrish
Glynn A
GA
Department of Clinical and Experimental Pharmacology, The University of Adelaide, and Department of Clinical Pharmacology, Royal Adelaide Hospital, Australia. glynn.morrish@adelaide.edu.au
Foster
David J R
DJ
Somogyi
Andrew A
AA
D000408:Alamethicin / Q000494:pharmacology; D000701:Analgesics, Opioid / Q000494:pharmacology*; D011431:Dextropropoxyphene / Q000494:pharmacology; D006801:Humans; D007476:Ionophores / Q000494:pharmacology; D008691:Methadone / Q000494:pharmacology*; D008692:Methadyl Acetate / Q000494:pharmacology; D008862:Microsomes, Liver / Q000187:drug effects / Q000378:metabolism; D009022:Morphine Derivatives / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics*
D000701:Analgesics, Opioid; D007476:Ionophores; D009022:Morphine Derivatives; D000408:Alamethicin; C035349:morphine-6-glucuronide; D008692:Methadyl Acetate; C018108:morphine-3-glucuronide; D011431:Dextropropoxyphene; D008691:Methadone